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============

The goal of therapy for open-angle glaucoma (OAG) is reduction of intraocular pressure (IOP) to prevent damage to the optic nerve and preserve visual function. Reduction of IOP can be achieved with medical therapy, laser procedures, and incisional surgery. In general, surgery is the most effective method of IOP reduction, but is also the most prone to adverse events, some of them sight-threatening. Traditional glaucoma surgical procedures, trabeculectomy and tube-shunt implantation, can provide greater IOP reductions and attain lower target IOP than medications or laser procedures \[[@CR1]--[@CR4]\]. These procedures, however, require the formation of a filtering bleb, which over time can develop leaks that can lead to hypotony and infections \[[@CR5]\]. In recent years, substantial innovation in surgical technique has sought to develop a procedure that provides IOP reduction comparable to that achieved with traditional surgery, but with a more favorable safety profile. Generally, these procedures avoid the formation of a bleb by shunting fluid across the obstructed trabecular meshwork (TM) into Schlemm's canal or into the suprachoroidal space. Overall, these procedures, termed micro-incisional glaucoma surgeries (MIGS), are safer than traditional glaucoma surgery, but have not consistently delivered comparable IOP reductions \[[@CR6], [@CR7]\]. More recently, in recognition of the bleb's key role in achieving significant IOP reductions, bleb-based MIGS procedures have been developed \[[@CR8], [@CR9]\]. Long-term safety of these procedures has yet to be established.

The Kahook Dual Blade (KDB; New World Medical, Rancho Cucamonga, CA, USA) is a single-use ophthalmic knife designed to perform a goniotomy procedure. The traditional goniotomy knife, usually a microvitreoretinal blade, is used to incise the trabecular meshwork behind Schwalbe's line and produces a single incision in the TM. Unfortunately, this technique does not remove TM tissue and may result in injuries to the adjacent sclera \[[@CR10]\]. Potential reasons for short- and long-term failure of incisional goniotomy include fusion of residual TM leaflets as well as scleral damage with resulting inflammation and localized scarring response \[[@CR11], [@CR12]\]. The KDB is a new ophthalmic blade, designed to remove the TM in a more complete fashion with minimal residual TM leaflets and less collateral damage \[[@CR10]\].

Herein, we present 12-month efficacy and safety outcomes of a series of cases in which patients with both medically treated OAG and visually significant cataract underwent phacoemulsification combined with goniotomy (PE + goniotomy) using the KDB.

Methods {#Sec2}
=======

This was a prospective, interventional case series of patients with both visually significant cataract and glaucoma undergoing PE + goniotomy using the KDB. De-identified data were collected from the practices at seven centers in North America using a standardized set of data collection forms.

This study was initiated after Institutional Review Board approval at each site. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study. Patients enrolled in this study were aged 18 or older with concurrent cataract and mild to severe glaucoma and scheduled for PE + goniotomy with KDB. In this study, indications for goniotomy were to reduce IOP and/or to reduce reliance on IOP-lowering medications at the time of cataract surgery in eyes with medically treated OAG while avoiding the formation of a filtering bleb and its associated risk profile. Patients in this study were selected for goniotomy if they had glaucoma that, in the judgment of the treating physician, would benefit from TM excision to remove diseased tissue and allow for unimpeded egress of aqueous into the distal outflow system.

This study had no formal protocol and was intended to descriptively characterize the impact of goniotomy with KDB on IOP and IOP medication use when combined with cataract surgery. Surgeons were invited to submit de-identified data collected prospectively on consecutive patients undergoing combined cataract and goniotomy in whom the indication for surgery was determined at each surgeon's discretion. The study was not registered as the ICMJE guidelines did not require it. Baseline and operative data were collected on the day of surgery, and the clinical course was assessed at 1 day, 1 week, and 1, 3, 6, and 12 months, postoperatively. Individual IOP goals were tailored to each individual patient at the discretion of each investigator; postoperatively, IOP-lowering medications were withdrawn or added as deemed necessary by each investigator.

Each investigator performed goniotomy using the KDB according to the manufacturer's directions for use. Goniotomy via TM excision performed with the KDB has been described elsewhere \[[@CR13]\]. The KDB has a distal tip that pierces the TM and enters Schlemm's canal (Fig. [1](#Fig1){ref-type="fig"}). As the instrument is advanced along Schlemm's canal, the TM is elevated on the KDB ramp and guided toward two parallel blades. Unlike a standard goniotomy knife that simply incises the TM, leaving contiguous anterior and posterior flaps, the KDB excises a strip of TM, leaving a direct opening for aqueous to pass from the anterior chamber into Schlemm's canal. Thus, goniotomy with KDB removes diseased tissue at the site of aqueous outflow obstruction, restoring the natural aqueous outflow pathway without the formation of a filtering bleb.Fig. 1Schematic of the single-use Kahook Dual Blade

The primary outcome for this study was IOP reduction from preoperative baseline. Mixed model analysis with a diagonal covariance matrix was utilized to evaluate longitudinal IOP changes over time and was adjusted for multiplicity using Bonferroni's method. Within-eye changes from baseline were compared using a paired *t* test. Two threshold measures of success were also defined: (1) an IOP reduction ≥ 20% from baseline and (2) IOP-lowering medical regimen reduced by ≥ 1 medication compared with preoperative therapy. The proportion of eyes attaining each of these threshold success criteria was reported at each time point. To best characterize success in meeting individual subject goals, a subgroup analysis was conducted to characterize IOP changes and medication changes over time in two subgroups: those with IOP greater than or equal to the median IOP and those with IOP less than the median IOP. Because the indication for surgery was not uniformly recorded in this study, it is assumed that the IOP reduction in the higher IOP subgroup approximates the IOP reductions expected in eyes undergoing surgery primarily for IOP reduction, while the medication reduction in the lower IOP subgroup approximates the medication reductions expected in eyes undergoing surgery for medication reduction. Safety was evaluated by tabulating both solicited and unsolicited adverse events from the intraoperative period through last follow-up. As this study was descriptive in nature and not designed to test a pre-specified hypothesis, no formal power/sample size analysis was conducted. Statistical analysis was conducted using SAS (PC Version 9.4, SAS Institute, Cary, NC, USA).

Results {#Sec3}
=======

Overall, data from 52 patients were included in this analysis, of whom 44 (84.6%) had primary OAG, 4 (7.7%) had pigmentary glaucoma, and 2 each (3.9% each) had normal tension glaucoma or exfoliation glaucoma. The majority of eyes (43/52, 82.7%) were using IOP-lowering medications at baseline, most commonly a prostaglandin analog (35/44, 79.6%).

Intraocular pressure data at baseline and each follow-up time point are given in Table [1](#Tab1){ref-type="table"} and Fig. [2](#Fig2){ref-type="fig"}. From a mean preoperative IOP of 16.8 ± 0.6 mmHg while using a mean of 1.6 ± 0.2 topical IOP-lowering medications, statistically significant IOP reduction was observed in the full sample as soon as postoperative day 1 and remained significant at every postoperative time point through 12 months of follow-up, ranging from 3.5 to 4.4 mmHg (*P *\< 0.001 at each time point), a 20.8--26.2% reduction. Similarly, the mean number of IOP-lowering medications was significantly lower at almost every postoperative visit compared to baseline, ranging from 0.5 to 1.0 (*P *\< 0.05 at each time point except month 3), a 37.5--68.8% reduction (Table [2](#Tab2){ref-type="table"}). At the month 12 assessment, mean IOP was 12.4 ± 0.3 mmHg (a mean of − 4.4 mmHg from baseline; *P *\< 0.001), a − 26.2% reduction. Eyes required 0.8 ± 0.1 medications on average (a mean reduction of 0.8 medications from baseline; *P *\< 0.05), a 50.0% reduction.Table 1Mean IOP over time: all eyes and low and high subgroupsAll eyes (*N* = 52)Baseline IOP ≤ 16.5 mmHg (*n* = 26)Baseline IOP \> 16.5 mmHg (*n* = 26)Mean IOP (mmHg) ± SE\*Mean difference (mmHg)IOP change (%)Mean IOP (mmHg) ± SEMean difference (mmHg)IOP change (%)Mean IOP (mmHg) ± SEMean difference (mmHg)IOP change (%)Baseline16.8 (0.6)--13.1 (0.4)--20.5 (0.6)--Day 112.7 (0.5)− 4.1− 24.412.3 (0.6)− 0.8− 6.113.2 (0.8)− 7.3− 35.6Week 112.7 (0.6)− 4.1− 24.412.4 (1.0)− 0.7− 5.313.1 (0.7)− 7.4− 36.1Month 113.3 (0.5)− 3.5− 20.813.4 (0.9)0.32.313.2 (0.5)− 7.3− 35.6Month 312.6 (0.4)− 4.2− 25.011.6 (0.6)− 1.5− 11.513.5 (0.5)− 7.0− 34.1Month 612.7 (0.4)− 4.1− 24.412.3 (0.5)− 0.8− 6.113.0 (0.6)− 7.5− 36.6Month 1212.4 (0.3)− 4.4− 26.212.6 (0.4)− 0.5− 3.812.2 (0.5)− 8.3− 40.5\*Reported are least squares means and associated standard errors from a mixed model for repeated measure analysis. Per Bonferroni pairwise comparison, the difference from baseline in mean IOP is statistically significant at each follow-up visit (*P* \< 0.001) Fig. 2Mean intraocular pressure (± standard error in mmHg) at each time point Table 2Mean medications over time: all eyes and low and high IOP subgroupsAll eyes (*n* = 52)Baseline IOP ≤ 16.5 mmHg (*n* = 26)Baseline IOP \> 16.5 mmHg (*n* = 26)Mean medication (*n*) ± SE\*Mean difference (*n*)Medication change (%)Mean medication (*n*) ± SEMean difference (*n*)Medication change (%)Mean medication (*n*) ± SEMean difference (*n*)Medication change (%)Baseline1.6 (0.2)----1.7 (0.2)----1.5 (0.3)--Day 10.5 (0.1)− 1.1− 68.80.7 (0.2)− 1.0− 58.80.4 (0.2)− 1.1− 73.3Week 10.6 (0.2)− 1.0− 62.50.7 (0.2)− 1.0− 58.80.6 (0.2)− 0.9− 60.0Month 10.7 (0.1)− 0.9− 56.30.8 (0.2)− 0.9− 52.90.6 (0.2)− 0.9− 60.0Month 31.0 (0.2)− 0.6− 37.50.8 (0.2)− 0.9− 52.91.1 (0.3)− 0.4− 26.7Month 60.8 (0.1)− 0.8− 50.00.7 (0.2)− 1.0− 58.81.0 (0.2)− 0.5− 33.3Month 120.8 (0.1)− 0.8− 50.00.6 (0.2)− 1.1− 64.71.0 (0.2)− 0.5− 33.3\*Reported are least squares means and associated standard errors from a mixed model for repeated measure analysis. Per Bonferroni pairwise comparison, the difference from baseline in mean medications is statistically significant at each follow-up visit (*P *\< 0.05) except at month 3 (*P *= 0.154)

The proportion of eyes achieving a minimum of 20% IOP reduction from baseline ranged from 54.4% to 67.4% throughout the first year and was 57.7% at the month 12 visit (Table [3](#Tab3){ref-type="table"}). Likewise, the proportion of patients whose topical IOP-lowering regimen was reduced by one or more medications ranged from 56.5% to 64.4%. These data are reported for all time points in Table [3](#Tab3){ref-type="table"}.Table 3Patients who met success criteria over time: all eyes and low and high IOP subgroupsAll eyes (*n* = 52)Baseline IOP ≤ 16.5 mmHg (*n* = 26)Baseline IOP \> 16.5 mmHg (*n* = 26)IOP reduction ≥ 20% (%)Medication reduction ≥ 1 (%)IOP reduction ≥ 20% (%)Medication reduction ≥ 1 (%)IOP reduction ≥ 20% (%)Medication reduction ≥ 1 (%)Day 125 (54.4)26 (56.5)5 (20.8)14 (58.3)20 (90.9)12 (54.6)Week 126 (57.8)29 (64.4)10 (41.7)18 (75.0)16 (76.2)11 (52.4)Month 127 (55.1)31 (63.3)5 (20.8)18 (75.0)22 (88.0)13 (52.0)Month 329 (67.4)26 (60.5)8 (38.1)18 (85.7)21 (95.5)8 (36.4)Month 628 (60.9)28 (60.9)6 (27.3)18 (81.8)22 (91.7)10 (41.7)Month 1230 (57.7)33 (63.5)4 (15.4)22 (84.6)26 (100.0)11 (42.3)

To better assess subject-specific goals, the efficacy analysis was repeated in two subgroups: those with baseline IOP ≤ 16.5 mmHg (the median IOP of the full group) and those with baseline IOP \> 16.5 mmHg (Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"}, [3](#Tab3){ref-type="table"}). In the lower IOP group, the primary goal of surgery is assumed to be medication reduction. In this group, medications were reduced by a mean of 0.9--1.1 medications across time points, with a mean medication reduction of 1.1 medications at month 12, at which time 85% of subjects had reduced their medication burden by one or more medications. This was achieved with no compromise of IOP control, as mean IOP remained stable with negligible changes across all study visits (mean changes ranging from 0.3 to − 1.5 mmHg). In the higher IOP group, where IOP reduction was likely the primary goal of surgery, mean IOP reductions ranged from 7.0 to 8.3 mmHg (34.1% to 40.5%), with mean IOP at month 12 being reduced by 8.3 mmHg (40.5%) and 100% of subjects achieving a minimum IOP reduction of 20%. These IOP reductions were accompanied by reductions in medications ranging from 0.4 to 1.1 medications, with subjects using a mean of 0.5 fewer medications at month 12.

Mean visual acuity improved from 0.439 ± 0.041 logMAR preoperatively to 0.137 ± 0.016 logMAR at 12 months postoperatively, representing a 0.302 ± 0.044 logMAR improvement (*P *\< 0.001).

Adverse events were non-sight threatening and self-limited. One eye each (1.9% each) experienced limited iridodialysis that healed without intervention and one peripheral tear in Descemet's membrane that spontaneously resolved. Sixteen eyes (30.8%) were noted to have intraoperative blood reflux as expected with unroofing of several collector channels. This is common in angle surgeries and is considered an expected observation rather than an adverse event. Generally only trace blood refluxed into the anterior chamber and resolved spontaneously in all cases typically within the 1st postoperative week. Postoperatively, pain/irritation was noted in four eyes (7.7%), posterior capsule opacification in two eyes (3.8%), and IOP spike \> 10 mmHg in two eyes (2.8%). No adverse events required secondary interventions (Table [4](#Tab4){ref-type="table"}).Table 4Intraoperative and postoperative adverse eventsAdverse eventNumber of eyes (*N* = 52)Incidence rate (%)Intraoperative Difficulty removing strip of trabecular meshwork23.8 Iridodialysis11.9 Tear in Descemet's membrane11.9Postoperative Pain/irritation47.7 Posterior capsule opacification23.8 Intraocular pressure spike \> 10 mmHg23.8 Cystoid macular edema11.9 Choroidal detachment11.9 Floater11.9 Glare11.9 Hazy vision11.9 Hypotony11.9 Peripheral anterior synechiae11.9 Tearing11.9

Discussion {#Sec4}
==========

This real-world study reflects the early experiences of seven surgeons performing combined cataract extraction and goniotomy with the Kahook Dual Blade. Our study demonstrates that goniotomy performed using the KDB can safely and significantly reduce both IOP (by 26.2%) and the need for IOP-lowering medications (by 50.0%) for at least 12 months when combined with cataract extraction in eyes with OAG and visually significant cataract. In subgroup analysis, 100% of eyes with higher baseline IOP achieved at least a 20% IOP reduction at month 12, and 85% of eyes with lower baseline IOP achieved at least a one medication reduction in treatment burden.

These results compare favorably with other MIGS procedures. In the pivotal trial of the iStent trabecular microbypass device, 66% of eyes undergoing combined surgery with cataract extraction achieved a minimum 20% IOP reduction without medication at 12 months \[[@CR14]\]. Similarly, in the pivotal trial of the Cypass suprachoroidal microstent, 82% of eyes undergoing combined surgery with cataract extraction achieved a minimum 20% IOP reduction at 12 months \[[@CR15]\]. The pivotal trial of Trabectome surgery did not report the proportion of patients achieving IOP or medication reduction goals, but the mean IOP reductions of about 40% and mean medication reductions of about 0.9 per eye are consistent with our outcomes in higher IOP and lower IOP eyes, respectively \[[@CR16]\]. A randomized trial comparing goniotomy with trabeculectomy reported 12-month IOP reductions of approximately 50% in both groups, which compares favorably with the 40.5% 12-month IOP reduction seen in our high-IOP subgroup; this study did not analyze postoperative medication reduction \[[@CR17]\]. Of note, the Trabectome ablates a strip of TM and the KDB excises a strip of TM; goniotomy incises but does not remove a strip of TM. The relative risk of surgical failure due to fusing of the residual TM leaflets between these procedures warrants future evaluation. Finally, cataract surgery alone is known to transiently reduce both IOP and the need for IOP-lowering medications in medically treated glaucoma patients. A recent meta-analysis revealed that the average magnitude of these reductions expected at 12 months from cataract surgery alone is 14% for IOP and 0.47 for IOP-lowering medications \[[@CR18]\]. In our series, mean reductions of 26.2% and 0.8%, respectively, were observed. Thus, cataract surgery alone is unlikely to account for the results obtained in this surgical series.

The intraoperative reflux of blood into the anterior chamber is common in this procedure and occurs in association with many other MIGS procedures \[[@CR7]\]. The reflux occurs when unroofing Schlemm's canal in the setting of intraoperative hypotony and should be considered an expected event in these surgical procedures. The blood typically resolves quickly and spontaneously without consequence.

This study was intended to describe early real-world experience with the KDB when used to perform goniotomy in combination with cataract surgery. In addition to clinical data, surgeons' experience with the KDB was assessed and has been reported previously \[[@CR13]\]. In 96--98% of cases, surgeons reported that the use of the KDB was straightforward, that entry into the canal with the KDB was uncomplicated, and that advancement of the KDB along the canal was smooth.

Limitations of this study include the small sample size and lack of a control group. While some of the IOP reductions observed may be attributable to cataract surgery alone, our results exceed the outcomes expected from cataract surgery alone and are consistent with outcomes of other MIGS procedures in combination with cataract surgery \[[@CR14]--[@CR16]\].

Conclusions {#Sec5}
===========

In summary, this study demonstrates that PE + goniotomy with the KDB performed in eyes with coexisting cataract and OAG provides significant reductions in both IOP and IOP-lowering medication use. The procedure provides a high probability of achieving subject-specific goals of IOP reduction and/or IOP medication reduction. Based on these data, this combined surgical approach is a valid treatment option in medically treated glaucoma patients undergoing cataract surgery in whom reduction of IOP, IOP-lowering medication burden, or both are desired. Ongoing and future studies will further characterize the long-term efficacy and safety of this procedure, compare its performance and cost effectiveness to other glaucoma surgical procedures, and evaluate its performance as a stand-alone procedure.
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